LUMEXA IMAGING HOLDINGS INC (LMRI) Fundamental Analysis & Valuation

NASDAQ:LMRI • US5502491062

Current stock price

11.84 USD
-0.88 (-6.92%)
At close:
11.84 USD
0 (0%)
After Hours:

This LMRI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. LMRI Profitability Analysis

1.1 Basic Checks

  • In the past year LMRI has reported negative net income.
  • LMRI had a positive operating cash flow in the past year.
LMRI Yearly Net Income VS EBIT VS OCF VS FCFLMRI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 0 -50M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -5.57%, LMRI is doing worse than 68.32% of the companies in the same industry.
  • LMRI has a Return On Equity of -56.31%. This is in the lower half of the industry: LMRI underperforms 71.29% of its industry peers.
Industry RankSector Rank
ROA -5.57%
ROE -56.31%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LMRI Yearly ROA, ROE, ROICLMRI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 -20 -40 -60

1.3 Margins

  • The Gross Margin of LMRI (10.14%) is worse than 74.26% of its industry peers.
  • LMRI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 10.15%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LMRI Yearly Profit, Operating, Gross MarginsLMRI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024 0 5 -5 10 -10

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. LMRI Health Analysis

2.1 Basic Checks

  • LMRI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, LMRI has about the same amount of shares outstanding.
  • The debt/assets ratio for LMRI is higher compared to a year ago.
LMRI Yearly Shares OutstandingLMRI Yearly Shares OutstandingYearly Shares Outstanding 2023 2024 20M 40M 60M 80M
LMRI Yearly Total Debt VS Total AssetsLMRI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2023 2024 500M 1B 1.5B

2.2 Solvency

  • LMRI has an Altman-Z score of 0.49. This is a bad value and indicates that LMRI is not financially healthy and even has some risk of bankruptcy.
  • LMRI has a worse Altman-Z score (0.49) than 75.25% of its industry peers.
  • The Debt to FCF ratio of LMRI is 6731.19, which is on the high side as it means it would take LMRI, 6731.19 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of LMRI (6731.19) is worse than 65.35% of its industry peers.
  • LMRI has a Debt/Equity ratio of 7.19. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 7.19, LMRI is not doing good in the industry: 80.20% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 7.19
Debt/FCF 6731.19
Altman-Z 0.49
ROIC/WACCN/A
WACC10.11%
LMRI Yearly LT Debt VS Equity VS FCFLMRI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2023 2024 200M 400M 600M 800M 1B

2.3 Liquidity

  • LMRI has a Current Ratio of 0.92. This is a bad value and indicates that LMRI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • LMRI has a Current ratio of 0.92. This is in the lower half of the industry: LMRI underperforms 77.23% of its industry peers.
  • A Quick Ratio of 0.92 indicates that LMRI may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.92, LMRI is doing worse than 72.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.92
Quick Ratio 0.92
LMRI Yearly Current Assets VS Current LiabilitesLMRI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. LMRI Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 23.01% over the past year.
  • The Revenue has been growing slightly by 1.38% in the past year.
EPS 1Y (TTM)23.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.33%
Revenue 1Y (TTM)1.38%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.78%

3.2 Future

  • The Earnings Per Share is expected to grow by 45.04% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, LMRI will show a small growth in Revenue. The Revenue will grow by 6.65% on average per year.
EPS Next Y101.44%
EPS Next 2Y67.47%
EPS Next 3Y45.04%
EPS Next 5YN/A
Revenue Next Year9.29%
Revenue Next 2Y7.13%
Revenue Next 3Y6.65%
Revenue Next 5YN/A

3.3 Evolution

LMRI Yearly Revenue VS EstimatesLMRI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
LMRI Yearly EPS VS EstimatesLMRI Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

3

4. LMRI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LMRI. In the last year negative earnings were reported.
  • LMRI is valuated correctly with a Price/Forward Earnings ratio of 14.78.
  • Based on the Price/Forward Earnings ratio, LMRI is valued a bit cheaper than 72.28% of the companies in the same industry.
  • LMRI's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.28.
Industry RankSector Rank
PE N/A
Fwd PE 14.78
LMRI Price Earnings VS Forward Price EarningsLMRI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

  • LMRI's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. LMRI is more expensive than 65.35% of the companies in the same industry.
  • LMRI's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. LMRI is more expensive than 64.36% of the companies in the same industry.
Industry RankSector Rank
P/FCF 6118.64
EV/EBITDA 113.03
LMRI Per share dataLMRI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • LMRI's earnings are expected to grow with 45.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y67.47%
EPS Next 3Y45.04%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LMRI Dividend Analysis

5.1 Amount

  • LMRI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LMRI Fundamentals: All Metrics, Ratios and Statistics

LUMEXA IMAGING HOLDINGS INC

NASDAQ:LMRI (3/20/2026, 8:06:11 PM)

After market: 11.84 0 (0%)

11.84

-0.88 (-6.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A
Earnings (Next)03-26
Inst Owners30.61%
Inst Owner ChangeN/A
Ins Owners1.67%
Ins Owner Change85.65%
Market Cap1.12B
Revenue(TTM)948.87M
Net Income(TTM)-94.10M
Analysts85
Price Target23.05 (94.68%)
Short Float %3.44%
Short Ratio0.94
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)-20.63%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0.08%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 14.78
P/S 1.18
P/FCF 6118.64
P/OCF 44.29
P/B 6.7
P/tB N/A
EV/EBITDA 113.03
EPS(TTM)-1
EYN/A
EPS(NY)0.8
Fwd EY6.76%
FCF(TTM)0
FCFY0.02%
OCF(TTM)0.27
OCFY2.26%
SpS10.03
BVpS1.77
TBVpS-7.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.57%
ROE -56.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 10.15%
FCFM 0.02%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 7.19
Debt/FCF 6731.19
Debt/EBITDA 55.8
Cap/Depr 66.4%
Cap/Sales 2.65%
Interest Coverage N/A
Cash Conversion 117.38%
Profit Quality N/A
Current Ratio 0.92
Quick Ratio 0.92
Altman-Z 0.49
F-ScoreN/A
WACC10.11%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.33%
EPS Next Y101.44%
EPS Next 2Y67.47%
EPS Next 3Y45.04%
EPS Next 5YN/A
Revenue 1Y (TTM)1.38%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.78%
Revenue Next Year9.29%
Revenue Next 2Y7.13%
Revenue Next 3Y6.65%
Revenue Next 5YN/A
EBIT growth 1Y-26.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1534.51%
EBIT Next 3Y162.45%
EBIT Next 5YN/A
FCF growth 1Y-4.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.56%
OCF growth 3YN/A
OCF growth 5YN/A

LUMEXA IMAGING HOLDINGS INC / LMRI Fundamental Analysis FAQ

What is the fundamental rating for LMRI stock?

ChartMill assigns a fundamental rating of 1 / 10 to LMRI.


What is the valuation status for LMRI stock?

ChartMill assigns a valuation rating of 3 / 10 to LUMEXA IMAGING HOLDINGS INC (LMRI). This can be considered as Overvalued.


Can you provide the profitability details for LUMEXA IMAGING HOLDINGS INC?

LUMEXA IMAGING HOLDINGS INC (LMRI) has a profitability rating of 0 / 10.


Can you provide the financial health for LMRI stock?

The financial health rating of LUMEXA IMAGING HOLDINGS INC (LMRI) is 0 / 10.